{"id":"intravaginal-prasterone","safety":{"commonSideEffects":[{"rate":"null","effect":"Vaginal discharge"},{"rate":"null","effect":"Vaginal bleeding"}]},"_chembl":{"chemblId":"CHEMBL3039094","moleculeType":"Small molecule","molecularWeight":"330.47"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by promoting the growth of the vaginal epithelium, increasing the levels of progesterone in the vagina, and reducing the symptoms of vaginal atrophy. This is achieved by mimicking the natural hormone progesterone, which is essential for maintaining the health of the vaginal tissue.","oneSentence":"Intravaginal prasterone is a vaginal progesterone that mimics the natural hormone progesterone to treat symptoms of menopause.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:42.699Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause"}]},"trialDetails":[{"nctId":"NCT06611514","phase":"PHASE3","title":"Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"European Institute of Oncology","startDate":"2024-12-01","conditions":"Women With Breast Cancer","enrollment":95},{"nctId":"NCT04982692","phase":"PHASE3","title":"A Clinical Study of INTRAROSA® (Prasterone) Vaginal Inserts in Postmenopausal Vulvovaginal Atrophy","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2021-09-13","conditions":"Postmenopausal Vulvovaginal Atrophy","enrollment":417},{"nctId":"NCT03854396","phase":"PHASE3","title":"Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women","status":"WITHDRAWN","sponsor":"Olivia Cardenas-Trowers, M.D.","startDate":"2020-05","conditions":"Recurrent Urinary Tract Infection, Postmenopause, Postmenopausal Syndrome","enrollment":""},{"nctId":"NCT03287232","phase":"PHASE3","title":"Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)","status":"COMPLETED","sponsor":"EndoCeutics Inc.","startDate":"2017-10-16","conditions":"Hypoactive Sexual Desire Disorder","enrollment":653},{"nctId":"NCT03740945","phase":"PHASE3","title":"Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer","status":"WITHDRAWN","sponsor":"EndoCeutics Inc.","startDate":"2018-11-06","conditions":"Vaginal Atrophy in Breast Cancer Patients","enrollment":""},{"nctId":"NCT03619005","phase":"PHASE3","title":"Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study","status":"WITHDRAWN","sponsor":"EndoCeutics Inc.","startDate":"2018-11-13","conditions":"Hypoactive Sexual Desire Disorder (HSDD)","enrollment":""},{"nctId":"NCT03782480","phase":"PHASE3","title":"Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy","status":"UNKNOWN","sponsor":"Center for Vulvovaginal Disorders","startDate":"2019-03-02","conditions":"Menopause, Genitourinary Syndrome of Menopause, Vulvovaginal Atrophy","enrollment":40},{"nctId":"NCT01256671","phase":"PHASE3","title":"DHEA Against Vaginal Atrophy - Safety Study of 12 Months","status":"COMPLETED","sponsor":"EndoCeutics Inc.","startDate":"2010-12","conditions":"Vaginal Atrophy","enrollment":530},{"nctId":"NCT01256684","phase":"PHASE3","title":"DHEA Against Vaginal Atrophy - 3-Month Efficacy Study","status":"COMPLETED","sponsor":"EndoCeutics Inc.","startDate":"2010-12","conditions":"Vaginal Atrophy","enrollment":255},{"nctId":"NCT02013544","phase":"PHASE3","title":"Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause","status":"COMPLETED","sponsor":"EndoCeutics Inc.","startDate":"2014-02","conditions":"Vaginal Atrophy","enrollment":558}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intrarosa"],"phase":"phase_3","status":"active","brandName":"intravaginal prasterone","genericName":"intravaginal prasterone","companyName":"Lee's Pharmaceutical Limited","companyId":"lee-s-pharmaceutical-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravaginal prasterone is a vaginal progesterone that mimics the natural hormone progesterone to treat symptoms of menopause. Used for Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}